Mathew Prasad
University of New Mexico, Department of Pediatrics, MSC 10 5590, 1 University of New Mexico, Albuquerque, New Mexico, 87131-0001, USA.
Thromb Haemost. 2004 Oct;92(4):738-46. doi: 10.1160/TH04-03-0163.
From its original envisioned use in patients with hemophilia and inhibitors, recombinant factor VIIa has been increasingly used in a variety of non-hemophilia bleeding/hemorrhagic situations with great efficacy. Most of the reported work has been in adult patients. This paper sets out to review its use in the pediatric non-hemophilia patients and the varied conditions it has been tried and used. Most of the published literature has shown that this agent is efficacious, safe and can be used as an adjunctive measure in the achievement of hemostasis. However, most of the published work is mainly anecdotal, case reports or small series. Randomized trials in children are eagerly awaited.
从最初设想用于血友病及抑制剂患者开始，重组凝血因子VIIa已越来越多地用于各种非血友病性出血/出血情况，且疗效显著。大多数已报道的研究针对成年患者。本文旨在综述其在儿科非血友病患者中的应用以及已尝试和使用的各种情况。大多数已发表的文献表明，该药物有效、安全，可作为实现止血的辅助措施。然而，大多数已发表的研究主要是轶事报道、病例报告或小系列研究。人们急切期待针对儿童的随机试验。
